share_log

信達生物：自願公告 - 瑪仕度肽在中國超重或肥胖受試者中的首個III期臨床研究達成主要終點和所有關鍵次要終點

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS

香港交易所 ·  Jan 8 18:30
Summary by Moomoo AI
信達生物製藥有限公司宣布，其研發的瑪仕度肽（IBI-362）在中國超重或肥胖成人受試者中進行的首個III期臨床研究（GLORY-1）達成了主要終點和所有關鍵次要終點。該研究評估了瑪仕度肽的有效性和安全性，結果顯示瑪仕度肽在減重和改善心血管代謝指標方面顯著優於安慰劑。公司計劃近期向國家藥品監督管理局遞交新藥上市申請。瑪仕度肽是與禮來製藥共同推進的GLP-1R/GCGR雙重激動劑，已在多項臨床研究中展現出優秀的療效。本公司將持續推動瑪仕度肽的其他適應症開發，並致力於心血管及代謝領域創新產品的研發。
信達生物製藥有限公司宣布，其研發的瑪仕度肽（IBI-362）在中國超重或肥胖成人受試者中進行的首個III期臨床研究（GLORY-1）達成了主要終點和所有關鍵次要終點。該研究評估了瑪仕度肽的有效性和安全性，結果顯示瑪仕度肽在減重和改善心血管代謝指標方面顯著優於安慰劑。公司計劃近期向國家藥品監督管理局遞交新藥上市申請。瑪仕度肽是與禮來製藥共同推進的GLP-1R/GCGR雙重激動劑，已在多項臨床研究中展現出優秀的療效。本公司將持續推動瑪仕度肽的其他適應症開發，並致力於心血管及代謝領域創新產品的研發。
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT ITS FIRST PHASE III CLINICAL STUDY (GLORY-1) IN OVERWEIGHT OR OBESE ADULT SUBJECTS IN CHINA (GLORY-1) HAS REACHED THE PRIMARY ENDPOINT AND ALL KEY SECONDARY ENDINGS. The study evaluated the efficacy and safety of marmoteptide, and the results showed that marmoteptide was significantly superior to placebo in terms of weight loss and improvement of cardiovascular metabolic indicators. The company plans to submit a new drug listing application to the National Drug Administration recently. MSDETOPEPTIDE IS A GLP-1R/GCGR DUAL STIMULANT CO-PROMOTED WITH LIRA PHARMACEUTICALS AND HAS SHOWN EXCELLENT EFFICACY IN SEVERAL CLINICAL STUDIES. The company will continue to promote the development of other indications for mastidine and to develop innovative products in the cardiovascular and metabolic fields.
SINDA BIOPHARMACEUTICAL CO., LTD. ANNOUNCED THAT ITS FIRST PHASE III CLINICAL STUDY (GLORY-1) IN OVERWEIGHT OR OBESE ADULT SUBJECTS IN CHINA (GLORY-1) HAS REACHED THE PRIMARY ENDPOINT AND ALL KEY SECONDARY ENDINGS. The study evaluated the efficacy and safety of marmoteptide, and the results showed that marmoteptide was significantly superior to placebo in terms of weight loss and improvement of cardiovascular metabolic indicators. The company plans to submit a new drug listing application to the National Drug Administration recently. MSDETOPEPTIDE IS A GLP-1R/GCGR DUAL STIMULANT CO-PROMOTED WITH LIRA PHARMACEUTICALS AND HAS SHOWN EXCELLENT EFFICACY IN SEVERAL CLINICAL STUDIES. The company will continue to promote the development of other indications for mastidine and to develop innovative products in the cardiovascular and metabolic fields.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more